Chirag Jhaveri, MD
Ophthalmology · Austin, TXNPI 1114117769
Payments from drug & device makers
Across 774 payments — averaging $12,136 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5.4M
- Genentech, Inc.$3M
- Boehringer Ingelheim$436K
- Boehringer Ingelheim International GmbH$133K
- Astellas Pharma US Inc$98K
- Regeneron$81K
- plus $213K from 21 others
Across 5 payments — averaging $1941.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$5K
- F. Hoffmann-la Roche AG$4K
- Novartis$857
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 74 | $5,421,042 |
| Genentech, Inc. | 217 | $3,012,298 |
| Boehringer Ingelheim | 22 | $435,674 |
| Boehringer Ingelheim International GmbH | 155 | $132,573 |
| Astellas Pharma US Inc | 62 | $98,010 |
| Regeneron | 63 | $80,748 |
| Sanofi US Services Inc. | 4 | $60,104 |
| AbbVie(2 entities) | 27 | $54,036 |
| Genentech USA, Inc. | 41 | $27,885 |
| Boehringer Ingelheim Finland Ky | 33 | $25,319 |
| Regeneron Healthcare Solutions, Inc. | 34 | $22,861 |
| AstraZeneca | 2 | $15,375 |
| F. Hoffmann-la Roche AG | 1 | $2,700 |
| GSK | 1 | $2,220 |
| Alimera Sciences, Inc. | 5 | $1,320 |
| Eyepoint US, Inc. | 7 | $367 |
| Ocular Therapeutix, Inc. | 8 | $307 |
| Biotissue Holdings Inc. | 2 | $205 |
| Optos, Inc. | 2 | $156 |
| Apellis Pharmaceuticals, Inc. | 5 | $139 |
| Harrow Eye, LLC | 2 | $36 |
| Biogen | 2 | $35 |
| Astellas Pharma Global Development | 1 | $30 |
| Alcon | 1 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $17 |
| Spark Therapeutics, Inc. | 1 | $11 |
How this compares
$9,393,518 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Austin
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.